PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients

Completed · Phase 4

Conditions studied: Transplantation, Liver

In brief

The purpose of this study is to measure the amount of MMF and tacrolimus concentration in the blood at a given time. Currently MMF is ordered as a set dose and tacrolimus is given based on body weight. While the deceased donor transplant receives the complete liver, in the live donor just over half of the liver is given (about 60%). The way these different types of transplants break down drugs could be different. Measuring the drug levels allows us to know what happens to the medication in between the morning and the evening dose.

Key facts

Study ID

NCT00178425

Run by

University of Rochester

People needed

24

Starts

2005-01-01

Expected to finish

2006-06-01

Last updated by the study team

2007-04-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult
• Female patients
• Negative pregnancy test
• Willing for contraception during the study period and 6 weeks after study

You may not qualify if…

• Serum Creatinine > 2.5 mg/dl
• On Dialysis
• HIV +ve
• Re-transplantation
• On Ventilator
• Multi-organ Transplant
• Platelets < 50,000
• WBC < 2,500

Where it is running

• University of Rochester — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.